TW200508247A - Sars - Google Patents

Sars

Info

Publication number
TW200508247A
TW200508247A TW093109694A TW93109694A TW200508247A TW 200508247 A TW200508247 A TW 200508247A TW 093109694 A TW093109694 A TW 093109694A TW 93109694 A TW93109694 A TW 93109694A TW 200508247 A TW200508247 A TW 200508247A
Authority
TW
Taiwan
Prior art keywords
sars
coronaviuses
virology
components
group
Prior art date
Application number
TW093109694A
Other languages
English (en)
Inventor
Bartholomeus Leonardus Haagmans
Thijs Kuiken
Ronaldus Adrianus Maria Fouchier
Albertus Dominicus Marcellinus Erasmus Osterhaus
Original Assignee
Vironovative Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vironovative Bv filed Critical Vironovative Bv
Publication of TW200508247A publication Critical patent/TW200508247A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW093109694A 2003-04-08 2004-04-08 Sars TW200508247A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03076037 2003-04-08
EP03076110 2003-04-14
EP03077307 2003-07-18

Publications (1)

Publication Number Publication Date
TW200508247A true TW200508247A (en) 2005-03-01

Family

ID=33162638

Family Applications (1)

Application Number Title Priority Date Filing Date
TW093109694A TW200508247A (en) 2003-04-08 2004-04-08 Sars

Country Status (8)

Country Link
US (1) US20070053878A1 (zh)
EP (1) EP1613650A2 (zh)
JP (1) JP2007528700A (zh)
KR (1) KR20060020610A (zh)
AU (1) AU2004228584A1 (zh)
CA (1) CA2521856A1 (zh)
TW (1) TW200508247A (zh)
WO (1) WO2004089983A2 (zh)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2435180C (en) 2001-01-19 2019-04-09 Vironovative B.V. A virus causing respiratory tract illness in susceptible mammals
EP1485468A4 (en) 2002-02-21 2007-01-03 Medimmune Vaccines Inc EXPRESSION SYSTEMS OF RECOMBINANT PARAINFLUENZA VIRUSES AND VACCINES COMPRISING HETEROLOGOUS ANTIGENS DERIVED FROM METAPNEUMOVIRUS
WO2004110392A2 (en) * 2003-04-01 2004-12-23 Intermune, Inc. Compositions and methods for treating coronavirus infection and sars
ES2529736T3 (es) * 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
EP1620061B1 (en) * 2003-04-28 2010-02-24 Sequoia Pharmaceuticals, Inc. Antiviral agents for the treatment, control and prevention of infections by coronaviruses
US20070248949A1 (en) * 2003-12-17 2007-10-25 Agency For Science, Technology And Research Sensitive and Specific Test to Detect Sars Coronavirus
WO2006076007A2 (en) * 2004-04-22 2006-07-20 Vanderbilt University Methods of detecting coronavirus infections
EP1619246A1 (en) * 2004-07-23 2006-01-25 Université de la Méditerranée, Aix-Marseille II RNA dependent RNA polymerases from coronavirus and their use in molecular biology and drug screening
WO2009124178A1 (en) * 2008-04-02 2009-10-08 Cornell Research Foundation, Inc. Method for prophylaxis or treatment of feline infectious peritonitis
CN103394097A (zh) * 2013-06-09 2013-11-20 东北农业大学 猪传染性胃肠炎和流行性腹泻两联疫苗的引物及制备方法
CN107033250B (zh) * 2017-05-23 2020-01-21 山东省农业科学院奶牛研究中心 牛冠状病毒重组多表位抗原及其应用
AU2021227687B2 (en) 2020-02-26 2023-02-23 Vir Biotechnology, Inc. Antibodies against SARS-CoV-2 and methods of using the same
KR102646366B1 (ko) * 2020-02-27 2024-03-12 충남대학교산학협력단 바이러스 유사 입자를 이용한 돼지 유행성 설사병 바이러스 백신 및 이의 제조방법
WO2022025029A1 (ja) * 2020-07-27 2022-02-03 国立大学法人滋賀医科大学 ｉｎ ｖｉｔｒｏにおいてコロナウイルス科に属するウイルスを増殖させる方法、コロナウイルス科に属するウイルスに対する中和抗体の産生方法、及びＳｅｖｅｒｅ ａｃｕｔｅ ｒｅｓｐｉｒａｔｏｒｙ ｓｙｎｄｒｏｍｅ ｃｏｒｏｎａｖｉｒｕｓ ２の感染モデルの製造方法
US11175293B1 (en) 2021-01-04 2021-11-16 University Of Utah Research Foundation Rapid assay for detection of SARS-CoV-2 antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT45559A (en) * 1987-01-16 1988-07-28 Duphar Int Res Process for producing new proteines and peptides of antigene activity and vaccines against virus of infective gastritis-enteritis
FR2828405B1 (fr) * 2001-08-09 2005-06-24 Virbac Sa Vaccin anti-coronavirus
ES2529736T3 (es) * 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS

Also Published As

Publication number Publication date
EP1613650A2 (en) 2006-01-11
US20070053878A1 (en) 2007-03-08
WO2004089983A2 (en) 2004-10-21
AU2004228584A1 (en) 2004-10-21
JP2007528700A (ja) 2007-10-18
WO2004089983A3 (en) 2005-01-20
KR20060020610A (ko) 2006-03-06
CA2521856A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
TW200508247A (en) Sars
SG149684A1 (en) A virus causing respiratory tract illness in susceptible animals
WO2003079757A3 (en) Hiv therapeutic
NO20070263L (no) Immunostimulerende oligonukleotidmultimerer
WO2006078645A3 (en) Heterologous polypeptide expression using low multiplicity of infection of viruses
WO2008033466A3 (en) Compositions and methods for treatment of viral diseases
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
TW200510412A (en) Oxime substituted imidazo-containing compounds
EP1793674A4 (en) SEQUENCE-SPECIFIC INHIBITION OF THE FUNCTION OF SMALL RNA
WO2004002940A8 (en) Inhibitors of hcv ns5b polymerase
WO2004058940A3 (en) Sirna-mediated gene silencing
PL1668001T3 (pl) Podstawione heteroarylobenzofuranowe kwasy
BRPI0414799A (pt) bifenilóxi-ácidos
AU2003284689A8 (en) Nucleic acid construct containing hepatitis c virus (hcv) of genocype 2a genome-origin nucleic acid and cell having the nucleic acid construct transferred thereinto
WO2007032794A3 (en) Inhibition of viral gene expression using small interfering rna
WO2007002639A3 (en) Non-nucleoside anti-hepacivirus agents and uses thereof
ATE375978T1 (de) Benzoylsulfonamide als antitumor-mittel
WO2004010925A3 (en) Mammalian genes involved in viral infection and tumor suppression
WO2005049814A3 (en) Novel atypical pneumonia-causing virus
WO2005051318A3 (en) Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
MY162185A (en) Alumina particles and methods of making the same
WO2005001039A3 (en) Ribozyme-regulated small inhibitory rna (sirna) production and methods of use thereof
WO2007120160A3 (en) Lactam containing hcv inhibitors
RS20060206A (en) Aminopyridine-derivatives as inducible no-synthase inhibitors
AU2002317474A1 (en) Human recombinant antibody against the hepatitis c (hcv) non structural ns3 protein, nucleic acid and uses thereof